KAK vs NexSample
Price, ratings, monetisation and update history for both apps, side by side โ with what reviewers say about each.
KAK
Read full descriptionHide full description
Quick risk-calculator for contrast-induced nephropathy based on validated clinical model KAK-CIN Score is a clinical decision-support tool designed to help healthcare professionals estimate the probability of Contrast-Induced Nephropathy (CIN) in patients who will receive intravascular contrast medium. The algorithm is based on the peer-reviewed study by Kulkarni et al (Indian Journal of Nephrology, 2023) which derived and validated a simplified risk score system. Key features: Input four key patient variables: Estimated Glomerular Filtration Rate (eGFR) Contrast volume (mL) Route of contrast administration (arterial vs intravenous) Presence or absence of Diabetes Mellitus Instantly calculates a risk-percentage for CIN and provides a risk category (e.g., low, moderate, high) and provides the CIN Score. Published Journal: https://indianjnephrol.org/?view-pdf=1&embedded=true&article=af81b65b1e790875fb17d4a368ca9457Aplh7GbponE%3D Why use KAK-CIN Score? The original study included 1,300 patients (derivation 1,000 + validation 300) with an observed incidence of CIN of 3.8 %. The model showed high sensitivity (90.4 %) and specificity (98.8 %) in the validation cohort. Unlike many prior CIN risk models that were limited to cardiac catheterisation, this score covers both intra-arterial and intravenous contrast exposure. Important disclaimer This app is for educational and decision-support purposes only. It does not replace clinical judgement, institutional protocols or specialist consultation. Use results in conjunction with the full clinical context. The authors are not responsible for any clinical outcomes resulting from use of this tool. Always follow local guidelines. Privacy & Security No patient-identifiable data is stored beyond your device.
NexSample
Read full descriptionHide full description
NexSample is a free sample size calculator for clinical research, designed for medical residents, fellows, postgraduate students, and researchers. It includes 26 calculators covering the most common study designs in clinical trials, observational research, and diagnostic studies, along with calculators for agreement, reliability, and regression that are hard to find elsewhere. Whether you are planning a thesis, protocol, dissertation, grant proposal, or manuscript, NexSample helps you calculate sample size quickly and accurately, with full formulas and references shown for every calculation.
Screenshots
Verdict
The clearest difference is update cadence: NexSample at weekly against KAK's fortnightly. KAK's advantage is iOS requirement (13.0 vs 15.1). On price, ads, in-app purchases and device support there is nothing between them.
Scored on Price ยท Rating ยท Positive reviews ยท Number of ratings ยท Update frequency ยท Ads ยท In-app purchases ยท Monetization ยท Best chart rank ยท Devices ยท Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
KAK ships an update fortnightly, NexSample weekly. The most recent releases landed on November 9, 2026 and November 13, 2026 respectively.
| Parameter | KAK | NexSample |
|---|---|---|
| Price | Free | Free |
| Update frequency | Fortnightly | Weekly โ better |
| Ads | No | No |
| In-app purchases | No | No |
| Devices | iPhone, iPad, iPod โ better | iPhone, iPod |
| Requires iOS | 13.0 โ better | 15.1 |
| Further details โ not scored | ||
| Size | 20 MB | 30 MB |
| Age rating | 4+ | 4+ |
| Developer | Mehulkumar Thakkar | M Jeeva Sankar |
In-app purchases
KAK
No in-app purchases
NexSample
No in-app purchases









